Benjamin Bonnard

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Src promotes tumor cell invasion by hijacking the translation machineries.

Src promotes tumor cell invasion by hijacking the translation machineries.

Journal: Cell reports

Published: June 19, 2026

Correction: The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice.

Correction: The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice.

Journal: Cardiovascular diabetology

Published: May 14, 2026

Tks5 interactome reveals endoplasmic-reticulum-associated translation machinery in invadosomes.

Tks5 interactome reveals endoplasmic-reticulum-associated translation machinery in invadosomes.

Journal: The FEBS journal

Published: March 14, 2025

The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice.

The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice.

Journal: Cardiovascular diabetology

Published: January 20, 2025

Src promotes tumor cell invasion by hijacking the translation machineries.

Src promotes tumor cell invasion by hijacking the translation machineries.

Journal: Cell reports

Published: August 10, 2024

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.

Journal: Journal of the American Heart Association

Published: June 06, 2024

Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetes.

Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetes.

Journal: PloS one

Published: March 22, 2024

Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway.

Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway.

Journal: Clinical science (London, England : 1979)

Published: February 25, 2024

NGAL is a Novel Target in Hypertension by Modulating the NCC-Mediated Renal Na Balance.

NGAL is a Novel Target in Hypertension by Modulating the NCC-Mediated Renal Na Balance.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: June 28, 2023

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.

Journal: International journal of molecular sciences

Published: December 16, 2022

Mineralocorticoid receptor activation contributes to intestinal fibrosis through neutrophil gelatinase-associated lipocalin in preclinical models.

Mineralocorticoid receptor activation contributes to intestinal fibrosis through neutrophil gelatinase-associated lipocalin in preclinical models.

Journal: Nature communications

Published: July 22, 2022

Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury.

Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury.

Journal: International journal of molecular sciences

Published: May 16, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026